These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8156540)

  • 21. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor cytotoxic T lymphocytes targeting solid tumors: ready for clinical trials.
    Rossig C
    Cytotherapy; 2012 Jan; 14(1):4-6. PubMed ID: 22103944
    [No Abstract]   [Full Text] [Related]  

  • 26. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of renal cell carcinoma.
    Haas GP; Hillman GG; Redman BG; Pontes JE
    CA Cancer J Clin; 1993; 43(3):177-87. PubMed ID: 8490757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
    Robertson CN; Linehan WM; Pass HI; Gomella LG; Haas GP; Berman A; Merino M; Rosenberg SA
    J Urol; 1990 Sep; 144(3):614-7; discussion 617-8. PubMed ID: 2201792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M
    Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma.
    Gomella LG; Ehya H; Steinberg SM; Rupp M; Merino M; Robertson C; Linehan WM
    J Surg Oncol; 1993 Aug; 53(4):252-5. PubMed ID: 8341057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphokine-activated killer traffic assay and our preliminary clinical results of regional arterial infusion of lymphokine-activated killer cells for renal cell carcinoma.
    Hayakawa M; Koyama Y; Williams RD; Osawa A
    Urol Int; 1991; 47 Suppl 1():127-31. PubMed ID: 1949369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-2: efficacy in renal cell carcinoma and overall safety profile.
    Louie A
    Cancer Invest; 1990; 8(2):315-6. PubMed ID: 2400958
    [No Abstract]   [Full Text] [Related]  

  • 33. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finding a place for tumor-specific T cells in targeted cancer therapy.
    Riddell SR
    J Exp Med; 2004 Dec; 200(12):1533-7. PubMed ID: 15611285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
    Schmidt-Wolf IG; Huhn D; Neubauer A; Wittig B
    Hum Gene Ther; 1994 Sep; 5(9):1161-8. PubMed ID: 7530496
    [No Abstract]   [Full Text] [Related]  

  • 38. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 40. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M
    Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.